Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 617316, 10 pages
http://dx.doi.org/10.1155/2015/617316
Research Article

Silencing of Eag1 Gene Inhibits Osteosarcoma Proliferation and Migration by Targeting STAT3-VEGF Pathway

1Department of Neurology, The Affiliated Southeast Hospital of Xiamen University, Zhangzhou 363000, China
2Department of Orthopaedics, The Affiliated Southeast Hospital of Xiamen University, Orthopaedic Center of People’s Liberation Army, Zhangzhou 363000, China
3Central Laboratory, The Affiliated Southeast Hospital of Xiamen University, Zhangzhou 363000, China

Received 26 August 2015; Accepted 3 November 2015

Academic Editor: Genichiro Ishii

Copyright © 2015 Xinyu Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Mirabello, R. J. Troisi, and S. A. Savage, “International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons,” International Journal of Cancer, vol. 125, no. 1, pp. 229–234, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. X. Dai, W. Ma, X. He, and R. K. Jha, “Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma,” Medical Science Monitor, vol. 17, no. 8, pp. RA177–RA190, 2011. View at Google Scholar · View at Scopus
  3. A. J. Mutsaers and C. R. Walkley, “Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells?” Bone, vol. 62, pp. 56–63, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Hameed and H. Dorfman, “Primary malignant bone tumors-recent developments,” Seminars in Diagnostic Pathology, vol. 28, no. 1, pp. 86–101, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. T. A. Guise, R. O'Keefe, R. L. Randall, and R. M. Terek, “Molecular biology and therapeutics in musculoskeletal oncology,” The Journal of Bone & Joint Surgery—American Volume, vol. 91, no. 3, pp. 724–732, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. D. S. Hawkins and C. A. S. Arndt, “Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy,” Cancer, vol. 98, no. 11, pp. 2447–2456, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. P. K. Wu, W. M. Chen, C. F. Chen, O. K. Lee, C. K. Haung, and T. H. Chen, “Primary osteogenic sarcoma with pulmonary metastasis: clinical results and prognostic factors in 91 patients,” Japanese Journal of Clinical Oncology, vol. 39, no. 8, pp. 514–522, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. L. A. Pardo, C. Contreras-Jurado, M. Zientkowska, F. Alves, and W. Stühmer, “Role of voltage-gated potassium channels in cancer,” Journal of Membrane Biology, vol. 205, no. 3, pp. 115–124, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. W. D. Kaplan and W. E. Trout III, “The behavior of four neurological mutants of Drosophila,” Genetics, vol. 61, no. 2, pp. 399–409, 1969. View at Google Scholar · View at Scopus
  10. C. K. Bauer and J. R. Schwarz, “Physiology of EAG K+ channels,” Journal of Membrane Biology, vol. 182, no. 1, pp. 1–15, 2001. View at Google Scholar · View at Scopus
  11. J. Camacho, “Ether à go-go potassium channels and cancer,” Cancer Letters, vol. 233, no. 1, pp. 1–9, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Hemmerlein, R.-M. Weseloh, F. M. de Queiroz et al., “Overexpression of Eag1 potassium channels in clinical tumours,” Molecular Cancer, vol. 5, article 41, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Weber, F. Mello de Queiroz, B.-R. Downie, A. Suckow, W. Stühmer, and L. A. Pardo, “Silencing the activity and proliferative properties of the human EagI Potassium Channel by RNA Interference,” The Journal of Biological Chemistry, vol. 281, no. 19, pp. 13030–13037, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. R. E. García-Ferreiro, D. Kerschensteiner, F. Major, F. Monje, W. Stühmer, and L. A. Pardo, “Mechanism of block of hEag1 K+ channels by imipramine and astemizole,” Journal of General Physiology, vol. 124, no. 4, pp. 301–317, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. L. A. Pardo, D. del Camino, A. Sánchez et al., “Oncogenic potential of EAG K+ channels,” The EMBO Journal, vol. 18, no. 20, pp. 5540–5547, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. V. Asher, H. Sowter, R. Shaw, A. Bali, and R. Khan, “Eag and HERG potassium channels as novel therapeutic targets in cancer,” World Journal of Surgical Oncology, vol. 8, article 113, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Wu, X. Wu, K. Lian, B. Lin, L. Guo, and Z. Ding, “Overexpression of potassium channel ether à go-go1 in human osteosarcoma,” Neoplasma, vol. 59, no. 2, pp. 207–215, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. X. Wu, D. Zhong, Q. Gao, W. Zhai, Z. Ding, and J. Wu, “MicroRNA-34a inhibits human osteosarcoma proliferation by downregulating ether à go-go 1 expression,” International Journal of Medical Sciences, vol. 10, no. 6, pp. 676–682, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. J. R. Agarwal, F. Griesinger, W. Stühmer, and L. A. Pardo, “The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia,” Molecular Cancer, vol. 9, article 18, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Hammadi, V. Chopin, F. Matifat et al., “Human ether à-go go K+ channel 1 (hEag1) regulates MDA-MB-231 breast cancer cell migration through Orai1-dependent calcium entry,” Journal of Cellular Physiology, vol. 227, no. 12, pp. 3837–3846, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Qian, S. Engst, K. Yamaguchi et al., “Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases,” Cancer Research, vol. 69, no. 20, pp. 8009–8016, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. B. R. Downie, A. Sánchez, H. Knötgen et al., “Eag1 expression interferes with hypoxia homeostasis and induces angiogenesis in tumors,” The Journal of Biological Chemistry, vol. 283, no. 52, pp. 36234–36240, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. S. L. Fossey, A. T. Liao, J. K. McCleese et al., “Characterization of STAT3 activation and expression in canine and human osteosarcoma,” BMC Cancer, vol. 9, article 81, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Niu, K. L. Wright, M. Huang et al., “Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis,” Oncogene, vol. 21, no. 13, pp. 2000–2008, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. X.-W. Ding, J.-J. Yan, P. An, P. Lü, and H.-S. Luo, “Aberrant expression of ether à go-go potassium channel in colorectal cancer patients and cell lines,” World Journal of Gastroenterology, vol. 13, no. 8, pp. 1257–1261, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Wu, D. Zhong, X. Fu, Q. Liu, L. Kang, and Z. Ding, “Silencing of Ether à go-go 1 by shRNA inhibits osteosarcoma growth and cell cycle progression,” International Journal of Molecular Sciences, vol. 15, no. 4, pp. 5570–5581, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Perrot-Applanat and M. Di Benedetto, “Autocrine functions of VEGF in breast tumor cells: adhesion, survival, migration and invasion,” Cell Adhesion & Migration, vol. 6, no. 6, pp. 547–553, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. E. B. Haura, J. Turkson, and R. Jove, “Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer,” Nature Clinical Practice Oncology, vol. 2, no. 6, pp. 315–324, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Germain and D. A. Frank, “Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy,” Clinical Cancer Research, vol. 13, no. 19, pp. 5665–5669, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. Q. Xu, J. Briggs, S. Park et al., “Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways,” Oncogene, vol. 24, no. 36, pp. 5552–5560, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Deng, J. Cui, N. Jiang et al., “STAT3 regulation the expression of VEGF-D in HGC-27 gastric cancer cell,” American Journal of Translational Research, vol. 6, no. 6, pp. 756–767, 2014. View at Google Scholar · View at Scopus
  32. M. Rokavec, M. G. Öner, H. Li et al., “IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis,” The Journal of Clinical Investigation, vol. 124, no. 4, pp. 1853–1867, 2014. View at Publisher · View at Google Scholar · View at Scopus